SCHEMBL26614213

SCHEMBL26614213

CC(C)CCC(=O)Nc1ccc2nc3n(c(=O)c2c1)-c1ccc(C#N)cc1C3=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDO2 P48775 15/20 0.43
▸ IDO1 P14902 14/20 0.43
▸ IDO2 Q6ZQW0 7/20 0.43
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ GLA P06280 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ APAF1 O14727 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ POLB P06746 1/20 0.40
▸ MAPK14 Q16539 1/20 0.39
▸ RORC P51449 1/20 0.38
▸ MITF O75030 1/20 0.38
▸ HSP90AA1 P07900 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30639065 1.00 TDO2 (0.43) TDO2IDO1IDO2KDM4EALDH1A1
SCHEMBL26614260 0.86 TDO2 (0.52) TDO2IDO1IDO2NPC1RAB9A
SCHEMBL31382842 0.81 TDO2 (0.46) TDO2IDO1IDO2NPC1RAB9A
SCHEMBL26857585 0.81 TDO2 (0.46) TDO2IDO1IDO2NPC1RAB9A
SCHEMBL26614240 0.76 TDO2 (0.54) TDO2IDO1IDO2NPC1RAB9A
SCHEMBL30639061 0.74 TDO2 (0.63) TDO2IDO1IDO2NPC1RAB9A
SCHEMBL26614153 0.74 TDO2 (0.63) TDO2IDO1IDO2NPC1RAB9A
SCHEMBL30639103 0.74 TDO2 (0.56) TDO2IDO1IDO2NPC1RAB9A
SCHEMBL30639117 0.74 TDO2 (0.56) TDO2IDO1IDO2NPC1RAB9A
SCHEMBL26614229 0.74 TDO2 (0.56) TDO2IDO1IDO2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. 2025-05-29 — — US disclosed
EP-4514804-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF Viscient Bio, Inc. (US) 2025-03-05 — — EP disclosed
WO-2023211977-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. (US) 2023-11-02 — — WO disclosed
WO-2023211977-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF VISCIENT BIO, INC. (US) 2023-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171452-A1 TRYPTANTHRIN DERIVATIVES AND USES THEREOF IDO2, IDO1, TPSB2 TDO2 8/4885IDO1 2/4885IDO2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback